Literature DB >> 22386395

Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates.

Christopher A Duplessis1, Mary Bavaro, Mark P Simons, Charles Marguet, Michael Santomauro, Brian Auge, Daniel A Collard, Joshua Fierer, James Lesperance.   

Abstract

OBJECTIVE: To test our hypothesis that a targeted rectal screening protocol before transrectal ultrasound (TRUS)-guided biopsy would potentiate streamlined prophylaxis, thereby reducing postbiopsy infectious rates while minimizing unnecessary broad-spectrum antibiotic use. To this end, we instituted preprocedure rectal cultures in an effort to identify fluoroquinolone (FQ)- resistant flora using selective media to optimally direct targeted prophylactic antibiotic administration. The inexorably increasing prevalence of multidrug-resistant microorganisms, notably extended spectrum beta lactamase (ESBL)-producing and FQ-resistant Enterobacteriaceae has increased the post-TRUS prostatic biopsy infection rates, including life-threatening sepsis.
METHODS: A total of 235 rectal swabs were obtained and plated directly onto MacConkey agar plates containing 10-μg/mL ciprofloxacin. Following the screening procedure, antimicrobial susceptibility results were used to develop a customized antibiotic prophylaxis regimen to be administered before biopsy. Following the biopsy procedure, the patients were seen in follow-up within 7 days, and information was gathered on potential adverse effects, clinical appointments for infections, and potential antibiotics received.
RESULTS: Thirty-two-patients (14%) had FQ-resistant isolates (most Escherichia coli), and 3 (1.3%) were ESBL-producing isolates. There were no infectious complications identified in this period, (compared with 3 septic complications among 103 biopsies in the 4 months preceding the study).
CONCLUSION: Rectal cultures obtained before TRUS biopsy, using selective media to identify FQ-resistant Enterobacteriaceae, facilitate targeted antibiotic prophylaxis, and appear to be highly efficacious in reducing infectious complications. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386395     DOI: 10.1016/j.urology.2011.09.057

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  43 in total

1.  Prostate cancer: the future of TRUS-guided biopsy antibiotic prophylaxis?

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2012-04-17       Impact factor: 14.432

Review 2.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

3.  Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial.

Authors:  Ahmed M Elshal; Ahmed M Atwa; Ahmed R El-Nahas; Mohamed A El-Ghar; Asaad Gaber; Essam Elsawy; Abdelwahab Hashem; Yasser Farag; Hashim Farg; Ali Elsorougy; Mohamed Fouda; Hossam Nabeeh; Ahmed Mosbah
Journal:  World J Urol       Date:  2018-05-07       Impact factor: 4.226

4.  Infective complications in patients after transrectal ultrasound-guided prostate biopsy and the role of ciprofloxacin resistant Escherichia coli colonization in rectal flora.

Authors:  Mustafa Bilal Hamarat; Fatih Tarhan; Rahim Horuz; Gülfem Akengin Öcal; Mehmet Kutlu Demirkol; Alper Kafkaslı; Özgür Yazıcı
Journal:  Turk J Urol       Date:  2017-05-03

Review 5.  Prevention and treatment of biopsy-related complications.

Authors:  Ramgopal Satyanarayana; Dipen Parekh
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

Review 6.  Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA.

Authors:  Stacy Loeb; Dean Assimos; Michael B Chancellor; J Curtis Nickel; Michael K Brawer; Adam J M Kern; Alan W Partin
Journal:  Rev Urol       Date:  2013

7.  An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy.

Authors:  Stephen J Summers; Darshan P Patel; Blake D Hamilton; Angela P Presson; Mark A Fisher; William T Lowrance; Andrew W Southwick
Journal:  World J Urol       Date:  2015-05-03       Impact factor: 4.226

8.  Performance Validation of Selective Screening Agars for Guiding Antimicrobial Prophylaxis in Patients Undergoing Prostate Biopsy.

Authors:  Sofie C M Tops; Marlie Bruens; Sacha van Mook-Vermulst; Diane Lamers-Jansen; Tobias Engel; Ger van den Brink; Rob van Duuren; Heiman F L Wertheim; Eva Kolwijck
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

9.  Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Authors:  K Lahdensuo; A Rannikko; V-J Anttila; A Erickson; A Pätäri-Sampo; M Rautio; H Santti; E Tarkka; M Vaara; K Huotari
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-16       Impact factor: 5.554

10.  Comparison of broth enhancement to direct plating for screening of rectal cultures for ciprofloxacin-resistant Escherichia coli.

Authors:  Michael A Liss; Kristen K Nakamura; Ellena M Peterson
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.